SELECT
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Patient / Population Intervention / Exposition Vergleich Endpunkt
In 17,604 patients with obesity and cardiovascular disease but without diabetes, semaglutide reduced major adverse cardiovascular events compared with placebo.
N
17.604
Design
Double-blind RCT
Endpunkt
CV death, MI or stroke
Relevanz
1
Ergebnis6.5 % vs 8.0 % (HR 0.80); mean weight loss 9.4 %.
Lincoff AM, et al. N Engl J Med. 2023;389(24):2221-2232. 10.1056/NEJMoa2307563
Diskussion & Kritik
First trial to show cardiovascular risk reduction from treating obesity itself, without diabetes. How much of the benefit is weight loss versus direct drug effect is unresolved.